Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698926 | 0.91 | SYK (0.33) | SYKCSNK2A1 | |
| SCHEMBL4696750 | 0.89 | SYK (0.32) | SYK | |
| SCHEMBL8818187 | 0.76 | SYK (0.34) | SYKCSNK2A1 | |
| SCHEMBL4044765 | 0.75 | PDPK1 (0.30) | — | |
| SCHEMBL23089683 | 0.74 | MAPT (0.37) | SYKCSNK2A1 | |
| SCHEMBL29814692 | 0.74 | MAPT (0.37) | SYKCSNK2A1 | |
| SCHEMBL29621739 | 0.74 | MT-CO2 (0.33) | — | |
| SCHEMBL26317889 | 0.74 | MT-CO2 (0.33) | — | |
| SCHEMBL8819965 | 0.71 | SYK (0.35) | SYK | |
| SCHEMBL23022156 | 0.70 | LCK (0.34) | SYKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1351959-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | SYK 2916/4885CSNK2A1 3233/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | SYK 2559/4885CSNK2A1 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.